Comparison of specific adsorbents for tumor necrosis factor-α and therapeutic anti-tumor necrosis factor-α antibodies: An in vitro sepsis model

International Journal of Artificial Organs

Volumn 29, Issue 12, 2006, Pages 1140-1147

  Schwanzer Pfeiffer, Dagmar ^a   Mitteregger, R ^a   Rossmanith, E ^a   Falkenhagen, D ^a  

^a DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

Endothelial adhesion molecules; Extracorporeal adsorptive therapy; Intensive care; MDS; Monocyte adhesion; Vascular disorder

Indexed keywords

ADHESION; ANTIBODIES; BODY FLUIDS; DETOXIFICATION; ENDOTHELIAL CELLS; GLYCOPROTEINS; PATIENT TREATMENT; TUMORS;

ADHESION MOLECULES; ENDOTHELIAL ADHESION MOLECULE; EXTRACORPOREAL ADSORPTIVE THERAPY; IN-VITRO; INTENSIVE CARE; MICROSPHERE-BASED DETOXIFICATION SYSTEM; MONOCYTE ADHESION; POLYCLONAL; TNF Α; VASCULAR DISORDER;

MACROPHAGES;

INFLIXIMAB; MICROSPHERE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADSORPTION; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DETOXIFICATION; ENDOTHELIUM CELL; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; SEPSIS; TECHNOLOGY; UMBILICAL VEIN;

EID: 33846471266     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880602901207     Document Type: Article

References (21)

1. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340: 207-14.
2. Steinhauser ML, Kunkel SL, Hogaboam CM. New frontiers in cytokine involvement during experimental sepsis. ILAR J 1999; 40: 142-50.
3. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101: 3765-77.
4. Patel KD, Cuvelier SL, Wiehler S. Selectins: critical mediators of leukocyte recruitment. Semin Immunol 2001; 14: 73-81.
5. Peters K, Unger RE, Brunner J, Kirkpatrick CJ. Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res 2003; 60: 49-57.
6. Viviani M, Berlot G, Gullo A. Epidemiology of infections in ICUs. Where are we? Sepsis and organ dysfunction. In: Baue AE, Berlot G, Gullo A, Vincent J-L (eds). Sepsis and organ dysfunction. Milan: Springer Verlag Italia; 2001. p 11-21.
7. Abraham E, Anzueto A, Gutierrez G, Tessier S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S. Double-blind randomised controlled trial of monoclonal antibodies to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351: 929-33.
8. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994; 271: 1836-43.
9. Arndt P, Abraham E. Immunological therapy of sepsis: experimental therapies. Intensive Care Med 2001; 27: S104-15.
10. Dellinger RP. Bad and good news in pathophysiology, prevention, and management of sepsis. In: Baue AE, Berlot G, Gullo A, Vincent J-L (eds). Sepsis and organ dysfunction. Milan: Springer Verlag Italia; 2001. p 63-73.
11. Weber V, Linsberger I, Ettenauer M, Loth F, Höyhtyä V, Falkenhagen D. Development of specific adsorbents for human tumor necrosis factor-α: Influence of antibodies immobilization on performance and biocompatibility. Biomacromolecules 2005; 6: 1864-70.
12. Gimbrone MA. Progress in hemostasis and thrombosis. In: Spaet TH, ed. New York: Grune & Stratton; 1976. Vol. 3, p 1-28.
13. Cell separation and protein purification. Technical Handbook; Dynal.
14. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989; 17: 975-8.
15. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-6.
16. Abraham E. Neutralizing antibodies and receptor constructs. In: Redl H, Schlag G (eds). Cytokines in severe sepsis and septic shock. Basel/ Switzerland: Birkhäuser Verlag; 1999. p 285-93.
17. Hanasawa. K. Extracoporeal treatment for septic patients: new adsorption technologies and their clinical application. Ther Apher 2002; 6: 290-5.
18. Tetta C, Bellomo R, Inguaggiato P, Wratten ML, Ronco C. Endotoxin and cytokine removal in sepsis. Ther Apher 2002; 6: 109-15.
19. von Appen K, Weber C, Losert U, Schima H, Gurland HJ, Falkenhagen D. Microspheres based detoxification system: a new method in connective blood purification. Artif Organs 1996; 20: 420-5.
20. Falkenhagen D, Schima H, Loth F. Arrangement for removing substances from liquids in particular blood. Europäisches Patent: 94 926 169.7, Japanisches Patent-No. 501083/97 US-Patent: 5.855.782/5. Jan. 99.
21. Falkenhagen D, Weber C, Schima H, Loth F, Rajnoch C, Vogt G, Moser H, Mitzner S. Eine neue Technologie der simultanen Filtration/Adsorption auf der Basis einer High-Speed - Rezirkulation von Nano- und Microspheres für die extrakorporale Blutreinigung. Biomed Tech (Berl) 1994; 39, 105-8.